MedTrace Logo

The PRISM Intervention for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation

NCT03640325 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2024-10-26

Study results available
· View outcomes & findings →

Summary

Multisite Randomized Controlled Trial (RCT) testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults receiving hematopoietic cell transplantation for hematology malignancy.

Conditions

  • Cancer
  • Bone Marrow Neoplasms
  • Anxiety
  • Depression
  • Quality of Life
  • Adherence, Medication
  • Coping Skills
  • Adolescent Behavior

Interventions

BEHAVIORAL

PRISM (Promoting Resilience in Stress Management)

Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making

Sponsors & Collaborators

Principal Investigators

  • Abby R Rosenberg, MD, MS, MA · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2023-03-31
Completion
2024-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03640325 on ClinicalTrials.gov